Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms

<b>Background/Objectives:</b> The feasibility of repurposing selective serotonin reuptake inhibitors as adjunctive antibacterial agents is an area of current investigation. We sought to evaluate if fluoxetine will achieve synergistic killing with relevant antibacterial drugs against skin...

Full description

Saved in:
Bibliographic Details
Main Authors: Samar A. Ahmed, Rondelle L. Jordan, Roslyn Rivkah Isseroff, Justin R. Lenhard
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/13/12/1165
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850239677501538304
author Samar A. Ahmed
Rondelle L. Jordan
Roslyn Rivkah Isseroff
Justin R. Lenhard
author_facet Samar A. Ahmed
Rondelle L. Jordan
Roslyn Rivkah Isseroff
Justin R. Lenhard
author_sort Samar A. Ahmed
collection DOAJ
description <b>Background/Objectives:</b> The feasibility of repurposing selective serotonin reuptake inhibitors as adjunctive antibacterial agents is an area of current investigation. We sought to evaluate if fluoxetine will achieve synergistic killing with relevant antibacterial drugs against skin and soft tissue pathogens and multidrug-resistant pathogens. <b>Methods</b>: The MIC of fluoxetine was determined using broth microdilution for a diverse isolate collection of 21 organisms. Checkerboard experiments were then conducted using fluoxetine and clinically relevant antibacterial drugs. If fluoxetine and an anti-infective agent achieved synergy denoted by a fractional inhibitory concentration index ≤ 0.5, then the combination was further evaluated in 24 h time-killing experiments. Synergy in time-killing experiments was defined as a ≥2 log<sub>10</sub> CFU/mL reduction in fluoxetine combined with an antibacterial agent at any point in the experiment in comparison to whichever agent in the combination resulted in the lowest bacterial counts individually. <b>Results</b>: The fluoxetine MICs ranged from 64 to 128 mcg/mL for Gram-positive isolates and 8–512 mcg/mL for Gram-negative organisms. Against Gram-positive isolates, vancomycin, linezolid, clindamycin, and gentamicin failed to achieve synergy in checkerboard experiments. Levofloxacin and fluoxetine were the only combination that demonstrated synergy against a Gram-positive pathogen in both checkerboard and time-killing experiments (1/6 isolates, 16.7%). Against Gram-negative organisms, the most promising combination was fluoxetine and polymyxin B, which achieved synergistic killing in both checkerboard experiments and time-killing experiments in 12/15 isolates (80%). In comparison, fosfomycin and meropenem achieved synergy in both experiments against 6/15 (40%) and 3/15 (20%) Gram-negative isolates, respectively. <b>Conclusions</b>: The combination of fluoxetine and polymyxin B may be a potential strategy for combatting difficult-to-treat Gram-negative pathogens.
format Article
id doaj-art-6aec98b7ca2e41bfa77a1c56880b292a
institution OA Journals
issn 2079-6382
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj-art-6aec98b7ca2e41bfa77a1c56880b292a2025-08-20T02:01:05ZengMDPI AGAntibiotics2079-63822024-12-011312116510.3390/antibiotics13121165Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant OrganismsSamar A. Ahmed0Rondelle L. Jordan1Roslyn Rivkah Isseroff2Justin R. Lenhard3Department of Clinical and Administrative Sciences, California Northstate University College of Pharmacy, Elk Grove, CA 95757, USADepartment of Clinical and Administrative Sciences, California Northstate University College of Pharmacy, Elk Grove, CA 95757, USADepartment of Dermatology, University of California Davis, Davis, CA 95816, USADepartment of Clinical and Administrative Sciences, California Northstate University College of Pharmacy, Elk Grove, CA 95757, USA<b>Background/Objectives:</b> The feasibility of repurposing selective serotonin reuptake inhibitors as adjunctive antibacterial agents is an area of current investigation. We sought to evaluate if fluoxetine will achieve synergistic killing with relevant antibacterial drugs against skin and soft tissue pathogens and multidrug-resistant pathogens. <b>Methods</b>: The MIC of fluoxetine was determined using broth microdilution for a diverse isolate collection of 21 organisms. Checkerboard experiments were then conducted using fluoxetine and clinically relevant antibacterial drugs. If fluoxetine and an anti-infective agent achieved synergy denoted by a fractional inhibitory concentration index ≤ 0.5, then the combination was further evaluated in 24 h time-killing experiments. Synergy in time-killing experiments was defined as a ≥2 log<sub>10</sub> CFU/mL reduction in fluoxetine combined with an antibacterial agent at any point in the experiment in comparison to whichever agent in the combination resulted in the lowest bacterial counts individually. <b>Results</b>: The fluoxetine MICs ranged from 64 to 128 mcg/mL for Gram-positive isolates and 8–512 mcg/mL for Gram-negative organisms. Against Gram-positive isolates, vancomycin, linezolid, clindamycin, and gentamicin failed to achieve synergy in checkerboard experiments. Levofloxacin and fluoxetine were the only combination that demonstrated synergy against a Gram-positive pathogen in both checkerboard and time-killing experiments (1/6 isolates, 16.7%). Against Gram-negative organisms, the most promising combination was fluoxetine and polymyxin B, which achieved synergistic killing in both checkerboard experiments and time-killing experiments in 12/15 isolates (80%). In comparison, fosfomycin and meropenem achieved synergy in both experiments against 6/15 (40%) and 3/15 (20%) Gram-negative isolates, respectively. <b>Conclusions</b>: The combination of fluoxetine and polymyxin B may be a potential strategy for combatting difficult-to-treat Gram-negative pathogens.https://www.mdpi.com/2079-6382/13/12/1165fluoxetinepolymyxinssynergy<i>Staphylococcus</i><i>Pseudomonas</i><i>Acinetobacter</i>
spellingShingle Samar A. Ahmed
Rondelle L. Jordan
Roslyn Rivkah Isseroff
Justin R. Lenhard
Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
Antibiotics
fluoxetine
polymyxins
synergy
<i>Staphylococcus</i>
<i>Pseudomonas</i>
<i>Acinetobacter</i>
title Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
title_full Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
title_fullStr Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
title_full_unstemmed Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
title_short Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms
title_sort potential synergy of fluoxetine and antibacterial agents against skin and soft tissue pathogens and drug resistant organisms
topic fluoxetine
polymyxins
synergy
<i>Staphylococcus</i>
<i>Pseudomonas</i>
<i>Acinetobacter</i>
url https://www.mdpi.com/2079-6382/13/12/1165
work_keys_str_mv AT samaraahmed potentialsynergyoffluoxetineandantibacterialagentsagainstskinandsofttissuepathogensanddrugresistantorganisms
AT rondelleljordan potentialsynergyoffluoxetineandantibacterialagentsagainstskinandsofttissuepathogensanddrugresistantorganisms
AT roslynrivkahisseroff potentialsynergyoffluoxetineandantibacterialagentsagainstskinandsofttissuepathogensanddrugresistantorganisms
AT justinrlenhard potentialsynergyoffluoxetineandantibacterialagentsagainstskinandsofttissuepathogensanddrugresistantorganisms